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Btcom¥cin-r©active iron swas detected in Ih¢ scra ofs/x out of nine adults undergoing- intensive chrmothcru W for acute non.lymphocytic leukemia. 
In these individuals the corresponding transfcrrin saturation ranged from 96"~ to I 13~ and the serum fcrritin from 775 to 99"/S,uWI. Nontransfcrrin- 
bound iron has bern postulated tob¢a factor in origin tc,xicky in iron overload conditiolLs such as beta tb.~hLSse~ and hereditary hemochromatosis 
by racilitatinll the production or tissuc.damailing f:¢e radicals. Wc propose that bleomycin.rcactiv¢ ron should L'c r, ons~'dcrrd asa possible factor 
in origen dysfunctiolt seen with intensive cancer chemotherapy, 
Non.transferrin bound iron: Acute non.lymphocytic leukemia. Cancer chemotherapy: l.':r¢¢ radials: Serum iron; Scram fcrrhln 
I. INTRODUCTION 
In iron overload conditions such as,8 thalassemia and 
hereditary hemochromatosis, an abnormal fraction of 
serum iron that is not bound to transferrin has been 
postulated to be a factor in organ toxicity [I.2], Such 
nontransfcrrin-bound iron might facilitate the produc- 
tion of free radicals that promote damage to lipids, 
proteins and DNA [3-6]. Patients treated with intensive 
cancer chemotherapy for acute non.lymphocytic leuke- 
mia regularly experience marked elevations in serum 
iron concentrations and transferrin sltturations [7] that 
are similar to values observed with iron overload. These 
patieat~ o~,¢a experience hepatic [8], pulmonary [9,10], 
and other organ dysfunction that may not be clearly 
related to chemotherapeutic agents, infections, or other 
identifiable causes. The capability of bleomycin to de- 
grade DNA in the presence of ferrous iron [11] has been 
used as the basis for an assay to m=asur¢ iron not bound 
to transferrin or ferritin in plasma of patiP.nts with iron 
overload [12.13]. Halliwell and colleagues found bleo- 
mycin-reactiv¢ iron in plasma samples from six sab,i:cts 
who were treated for acute non-lymphocytic leukemia 
[t4]. Such an abnormal iron fraction might be a poten- 
tial cause of some organ toxicity, We examined tl~e sere 
of nine patients with acute non-lymphocytic leukemia 
for the presence of bleomycin-reactive ron before, dur- 
ing and after intensive chemotherapy, 
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2. MATERIALS  AND METHODS 
Serial scru ,r. samples w~re prosi~ctively obtained with inform¢d 
consent from patients undrrl|oing chemotherapy for acute +ton.lyre- 
phocyti¢ leukemia :Lt Mctrol'lealth Medical Center or University Hop 
pi|als of Clcv~h~nd, Nontransfcrrin-bound iron ',,,'as measured using 
the blcomycin assay [13] as drs~rih¢d, except l~at rcra was u~ in- 
stead of plasnla, S~rum iron and total iron binding capacity (TIBC) 
were measured using methods of (he [ntrrnatim~al Committee for 
Standardization in Hematology. modified to be um:d for small quanti- 
ties of~rum [iS. 16l.-',+d t~nsrerrin saturation was reticulated. Sert~m 
ferritin was n~casurrd USilIB FER-IRON immunoradiomctric a~,ay 
kits (Ram¢o Labontmri~. Inc., Houston. TX). 
3, RESULTS 
Nine patients were studied (Table 1), including seven 
males and two females with ages ranging from 24 to 64 
years, Seven patients received induction chemotherapy 
regimens (two for initial treatment, five for relapsed 
leukemia) and two patients were given consolidation 
therapy, Chemotherapeutic drugs included cytosine ar- 
abinoside (8 patients), daunorubicin (5 patients), 6- 
thioguanine (3 patients), amsacrine (1 patient), mi- 
toxantrone (l patient) and etoposide (1 patient), Dura- 
tion of chemotherapy ranged from 5 to 9 days, median 
7. 
Bleomycin-detectable iron was identified in th,~ sere 
of six of the nine patient~ from I to 6 days after chemo- 
therapy was started, Before onset of chemotherapy only 
two patients had bleomycin-reactiv¢ iron. In two pa- 
tient~ with bleomycin-detectable iron. repeat analysis 
demonstrated that it persisted on day 11. In all of six 
patients tested 12 to 29 days after onset of chemother- 
apy no bleomycin.reactive ron was lbund. 
At the tim~ bleomycin-detcctable ironwas fo,nd, the 
corresponding transferrin saturation was greater than 
95% in all but one serum sample. 
4 Puhlished hy Elsevier Selectee Publishers B. V. 
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4. DI£CUSSION 
Over one-half of patients with acute non-lymphocytic 
leukemia who are treated with intensive chemotherapy 
develop elevations of hepatic enzymes [9.17], Although 
these patients receive multiple blood products and are 
at a high risk for transfusion associated viral hepatitis, 
not all hepatic dysfunction isclearly related to this etiol- 
ogy, Some patients develop hepatic venu-uucl-~iv¢ dis- 
ease, a condition that is not typical of viral hepatitis and 
has high mortality, Among patients undergoing bone 
marrow transplantation for malignancy, up to 21% de- 
velop hepatic veno-occlusiv¢ disease it 8,19], 
Unexplained pulmonary dysfunction is also common 
in patients treated with intensive cancer chemotherapy. 
In an autopsy series of patients with leukemia t Johns 
Hopkins Hospital, 42 of 51 patients who had received 
chemotherapy within 30 days of death had evidence of 
pulmonary edema it0], In one-third of these, a cause 
(i.c. infection, cardiac failure, renal failure, aspiration) 
for the pulmonary edema could he found, but two- 
thirds of the cases were idiopathic. The investigators 
attributed those pulmonary abnormalities to cytosine 
arabinoside toxicity, but the evidence for this was only 
circumstantial. In another series from the National 
Cancer Institute studying antibiotic therapy in cancer 
patients with fever and neutropenia. 6 of 33 deaths were 
due to pneumonit[s and respiratory hilure of undeter- 
mined cause [l l]. In three recent studies documenting 
the o~urrcnce of adult respiratory distress yndrome in 
neutropenic pati¢nts [20-22]. most of  the patients re- 
ported were cancer patients who had recently received 
chemotherapy, 
Our data suggest hat. in patients treated with inten- 
sive cancer chemotherapy, the circulation may be pre- 
sented with iron in exc=ss of what can be bound to the 
highly saturated transferrin molecules, and that in some 
patients iron that is detectable by the bl¢omycin a=ay 
is present. In most of the== patients there are markedly 
elevated s=rua~ f¢¢tltin concentrations (Table I) that 
most likely are related, at least in part, to lysis of leuke- 
mic cells and release of tissue ferritin. Although Pootra- 
kuI and colleagues [23] have propped that iron con- 
rained in plasma fcrritin is an explanation for non. 
transferrin iron, the bleomycin assay report~ly does 
not detect iron contained in concentrated solutions of 
t'erritin that is fully saturated with iron [13]. 
Under normal circumstances circulating iron is 
tightly bound to transferrln so that there is virtually no 
free iron in the plasma [13]. The presence of iron not 
bound to transt'~rrin  the serum is distinctly abnormal 
and might ~Luse formation of the highly reactive and 
damaging hydroxyl radical leading to ptroxidation of 
membrane iipids and tissue damage [3,24]. We propose 
that circulating bleomycin-reactive iron should be con- 
sidered as a possible factor in some cases of  hepatic. 
palmon:Lry. ~nd other dysfunction seen during intensive 
chemotherapy. Iron chelation conceivably might lag 
protective for some toxicity seen in patients with acute 
non-lymphocytic leukemia [251, 
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